MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2016 International Congress

    Motor features and response to levodopa in Parkinson’s disease with normal olfactory function

    M. Rossi, A. Medina Escobar, A. Bril, P. Millar Vernetti, J.I. De Palo, D. Cerquetti, M. Merello (Buenos Aires, Argentina)

    Objective: The aim of this study was to evaluate motor features in the OFF and ON states and the acute levodopa response in Parkinson's disease…
  • 2016 International Congress

    Increased energy expenditure in early Parkinson’s disease during exercise

    T. Margaliot Kalifa, N. Ziv, H. Bergman, S. Nusair, D. Arkadir (Jerusalem, Israel)

    Objective: To measure both resting energy expenditure rate (REER) and energy expenditure during mild to moderate exercise in patients with early Parkinson's disease (PD) that…
  • 2016 International Congress

    Effectiveness of duodenal levodopa/carbidopa infusion gel (LCIG) therapy on the neuropsychiatric disturbances of advanced Parkinson’s disease (EDIS study)

    M.J. Catalan, P. Montero, J. Herreros, J.M. Arbelo, P. Martinez-Martin (Madrid, Spain)

    Objective: To evaluate the effectiveness of LCIG on neuropsychiatric disturbances in advanced Parkinson's disease (APD) patients. Background: Neuropsychiatric disorders are prevalent in PD and may…
  • 2016 International Congress

    Predicting medication reduction in Parkinson’s disease patients after deep brain stimulation

    S.A. Dodwell, C.E. Ashton, D.K. Simon, D. Tarsy, E. Papavassiliou, R. Alterman, L. Shih (Boston, MA, USA)

    Objective: To determine which factors predict medication reduction for Parkinson's disease (PD) patients after deep brain stimulation (DBS) of the bilateral subthalamic nucleus (STN). Background:…
  • 2016 International Congress

    A multi-centre European comparative survey of advanced therapies (infusion and deep brain stimulation) in Parkinson’s disease

    A.M. Rizos, P. Martinez-Martin, P. Reddy, M. Silverdale, K. Ashkan, A. Antonini, D. Calandrella, P. Odin, T. Henriksen, N. Bryndum, A. Glad, M.G. Kramberger, Z. Pirtošek, M. Trošt, T. van Laar, R. Katzenschlager, H.S. Dafsari, L. Timmermann, A. Storch, H. Reichmann, K. Ray Chaudhuri, On behalf of EUROPAR, The IPMDS Non-Motor PD Study Group (London, United Kingdom)

    Objective: To address comparative demographic and other variables for Parkinson's disease patients at baseline for infusion therapies (subcutaneous apomorphine (Apo), intrajejunal levodopa (IJLI)) and deep…
  • 2016 International Congress

    Clinical effect and dose conversion of rytary (numient) in 50 consecutive patients with PD motor fluctuations

    N. Chhabria, S.H. Isaacson (Boca Raton, FL, USA)

    Objective: To review the clinical use of a newer extended-release levodopa preparation in 50 consecutive patients with PD experiencing motor fluctuations on immediate-release levodopa. Background:…
  • 2016 International Congress

    Chronic levodopa treatment accelerates the disorders of circadian rhythm in 6-OHDA induced Parkinson’s disease model

    S. Li, Y. Wang, W. Liu, D. Lv, C. Liu (Suzhou, People's Republic of China)

    Objective: We aimed to study the effect of levodopa on circadian rhythms in 6-OHDA lesioned rats, and to clarify whether the disturbance of the circadian…
  • 2016 International Congress

    Long-duration response to levodopa in Parkinson’s disease is independent of disease duration: A prospective study on de novo patients in Ghana

    R. Cilia, E. Cereda, M. Amboni, A. Akpalu, F.S. Sarfo, M. Cham, M. Fabbri, G. Pezzoli (Milan, Italy)

    Objective: To prospectively investigate the response to acute levodopa challenge in patients with advanced Parkinson's disease (PD) never treated before. Background: Pathophysiological mechanisms underlying motor…
  • 2016 International Congress

    Phenotypic spectrum and longitudinal outcome of Parkinson’s disease patients with psychosis

    M.S. Nanjunda Swamy, M.M. Abbas, S.T. Govindappa, P. Basu, R. Ramanathan, U.B. Muthane (Bangalore, India)

    Objective: We studied the phenotypic characteristics of psychosis in PD patients, their associated risk factors and assessed their long term outcome. Background: Psychosis in PD…
  • 2016 International Congress

    Levodopa/carbidopa intestinal gel, neuropathy, and B-vitamins – Is there an association?

    S. Löns, E. Chorbadgieva, A. Kleimann, D. Dressler, C. Schrader (Hannover, Germany)

    Objective: To assess the frequency of neuropathy and its neurophysiological characteristics in orally and levodopa/carbidopa intestinal gel (LCIG) treated patients with advanced idiopathic Parkinson´s disease…
  • « Previous Page
  • 1
  • …
  • 63
  • 64
  • 65
  • 66
  • 67
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley